Zydus Lifesciences Limited · NSE:ZYDUSLIFE
Zydus Lifesciences — Q4 FY23 Earnings Presentation
15 slides from Zydus Lifesciences's earnings presentation, May 18, 2023
Slide 1: Exchange filing cover letter: Investor Presentation
May 18, 2023 Listing Department Code: 532321 BSE LIMITED P J Towers, Dalal Street, Mumbai–400 001 Listing Department Code: ZYDUSLIFE NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, C/1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai–400 051 Re: Investor Presentation Dear Sir, Please find
Slide 2: Earnings Presentation: Q4 and Full Year FY23
Zydus Lifesciences Limited Earnings Presentation: Q4 and Full Year FY23 18th May, 2023 1
Slide 3: Disclaimer and Safe Harbor Statement
Disclaimer and Safe Harbor Statement • THIS PRESENTATION (PRESENTATION) IS NOT AN OFFER TO SELL ANY SECURITIES OR A SOLICITATION TO BUY ANY SECURITIES OF ZYDUS LIFESCIENCES LIMITED OR ITS SUBSIDIARIES OR JOINT VENTURES (TOGETHER, THE “COMPANY”). The material that follows is a Presentation of general
Slide 4: Q4 FY23: At a Glance
Q4 FY23: At a Glance Revenues from Highlights of Q4 FY23 R&D Operations* ❑ Total revenues grew 32% yoy, led by US formulations business. Rs. 50,106 mn Rs. 3,541 mn ❑ India formulations business continued to deliver consistent performance 32% YoY 7.1% of revenues with 12% yoy ex-COVID growth (reporte
Slide 5: Key Financial Metrics (1/2)
Key Financial Metrics (1/2) Total Revenues (Rs. mn) Gross Profit (Rs. mn) and Gross Margin % 60.7% 64.5% 66.2% 63.3% 63.4% 172374 50,106 1,09,273 151099 33,146 38,056 42,571 95,647 27,467 23,098 Q4FY22 Q3FY23 Q4FY23 FY22 FY23 Q4FY22 Q3FY23 Q4FY23 FY22 FY23 Total R&D (Rs. mn) and % to Revenues EBITDA
Slide 6: Key Financial Metrics (2/2)
Key Financial Metrics (2/2) PAT ex. Exceptional, One-offs and Discontinued ops.(Rs. mn) Organic Capex (Rs. mn) 9,001 26608 11,218 22988 2,668 2,554 9,579 6,225 5,250 2,040 Q4FY22 Q3FY23 Q4FY23 FY22 FY23 Q4FY22 Q3FY23 Q4FY23 FY22 FY23 Net Debt/ EBITDA Net Working Capital* (Rs. mn) 56,290 57,051 51,21
Slide 7: India Formulations business
India Formulations business Sustained growth momentum driven by focused execution Highlights for the quarter India Formulations Sales Q4 FY23 Revenue India Formulations Sales (Rs. mn) Contribution (Rs. mn) ▪ The business grew by 11% YoY, ex-COVID opportunities, the growth was 12% YoY. 12,316 12,896
Slide 8: Consumer Wellness
Consumer Wellness Leveraging strong brand equity to navigate through challenging times Highlights for the quarter Consumer Wellness Sales Q4 FY23 Revenue Consumer Wellness Sales (Rs. mn) Contribution (Rs. mn) ▪ Consumer sentiments recovered gradually during 6,330 7,075 22,338 the quarter. However, u
Slide 9: US Formulations business
US Formulations business Delivering sustained sequential growth through the year Highlights for the quarter US Formulations Sales Q4 FY23 Revenue US Formulations Sales (Rs. mn) Contribution (Rs. mn) ▪ Received 28 new product approvals (incl. 5 tentative 22,525 74,451 approvals) and launched 8 new pr
Slide 10: Emerging Markets & Europe Formulations business
Emerging Markets & Europe Formulations business Base business continued to display robust growth Highlights for the quarter EM & EU Formulations Sales Q4 FY23 Revenue EM & EU Formulations (Rs. mn) Contribution Sales (Rs. mn) ▪ The business grew by 34% YoY, excluding revenue of 4,393 15,794 COVID rel
Slide 11: Updates on Innovation
Updates on Innovation NCE: Saroglitazar Magnesium • The molecule is undergoing Phase II(b) clinical trials for NASH indication for the US market. It received approval from the regulatory authority of Turkey to conduct clinical trials for this indication. NCE: ZYIL1 (NLRP3 inhibitor) • USFDA granted
Slide 12: Zydus at a Glance
Zydus at a Glance ~$2.15 bn Global Revenues1 5th Largest generic Co. in US in terms of prescription3 7 R&D Centers For NCE, APIs, Gx formulations, Biosimilars and Vaccines Among 1st Revenues from India Approved product for >40% In 65% of product Geography (Formulations Top 3 families marketed in US4
Slide 13: Consolidated Financial Performance (reported)
Consolidated Financial Performance (reported) Q4 Q4 YoY Q3 QoQ YoY Rs. mn FY23 FY22 Comments for Q4 FY23 FY23 FY22 gr. FY23 gr. gr. Total Income from Ops. 50,106 38,056 31.7% 42,571 17.7% 1,72,374 1,51,099 14.1% • YoY growth in total income from Gross Contribution (GC) 33,146 23,098 43.5% 27,467 20.
Slide 14: Details of Exchange Rate Fluctuations
Details of Exchange Rate Fluctuations Q4 Q4 YoY YoY Rs. mn FY23 FY22 FY23 FY22 gr. % gr. % A. On operating transactions (above EBITDA line) 590 -516 214.2% -3,049 -1,468 -107.7% a. Included in COGS 5 66 -93% -205 85 -341.1% b. Part of other operating expenses (shown separately) 585 -582 -2,844 -1,55
Slide 15: Thank you
Thank you For any queries, please contact Arvind Bothra Arvind.Bothra@zyduslife.com +91-22-62711905 For more information, please visit: www.zyduslife.com Registered Office: www.linkedin.com/company/zyduslife Zydus Corporate Park, Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi C